Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase ii study

Mease, Philip J; Gladman, Dafna D; Deodhar, Atul; McGonagle, Dennis G; Nash, Peter; Boehncke, Wolf-Henning; Gottlieb, Alice; Xu, Xie L; Xu, Stephen; Hsia, Elizabeth C; Karyekar, Chetan S; Helliwell, Philip S

doi:10.1136/rmdopen-2020-001217

Scientific article

English

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase ii study

ContributorsMease, Philip J; Gladman, Dafna D; Deodhar, Atul; McGonagle, Dennis G; Nash, Peter; Boehncke, Wolf-Henning; Gottlieb, Alice; Xu, Xie L; Xu, Stephen; Hsia, Elizabeth C; Karyekar, Chetan S; Helliwell, Philip S

Published inRMD Open, vol. 6, no. 2

Publication date2020

Abstract

To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA).

Keywords

Ankylosing Spondylitis
Anti-TNF
Arthritis
Chemokines
Disease Activity
Lupus Nephritis
Psoriatic Arthritis
Rheumatoid Arthritis
Spondyloarthritis
Systemic Lupus Erythematosus
TNF-alpha
Treatment

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Inflammation cutanée (919)

Citation (ISO format)

MEASE, Philip J et al. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase ii study. In: RMD Open, 2020, vol. 6, n° 2. doi: 10.1136/rmdopen-2020-001217